The Latest Cardiac and Vascular News
SAN DIEGO, Sept. 17, 2019 /PRNewswire/ — Abcentra, a clinical-stage bio-pharmaceutical company that addresses unmet needs in inflammation, today announced its contribution to a 2019 study published in the American Heart Association Journals. The study found that, in those with high-cholesterol and major histocompatibility complex class II (MHCII) cells, treating atherosclerosis with immunotherapy […]
– World’s smallest pediatric treatments pioneered by Abbott address critical needs for the most vulnerable patients: babies and children born with common congenital heart defects – Includes pediatric mechanical heart valve and first minimally invasive device to treat premature babies and newborns born with an opening in their heart […]
SALT LAKE CITY–(BUSINESS WIRE)–Foldax, Inc. today announced its first-in-human use of the Tria heart valve under its FDA Early Feasibility Study (EFS) for the treatment of aortic valve disease. Clinicians at Beaumont Hospital, Royal Oak, in Michigan, implanted this innovative flexible polymer heart valve, which has the potential to address […]
WINNIPEG, Sept. 17, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the launch of the ReDSTM PRO (“ReDSTM PRO”) system, the next generation of lung fluid management technology for heart failure. The debut of the new system took place at the recent Heart […]
Non-invasive monitoring technology assists in managing heart failure patients TENAFLY, N.J., Sept. 14, 2019 /PRNewswire/ — Sensible Medical Innovations today announced the launch of the ReDSTM PRO system. The debut of the new system was at the Heart Failure society of America conference in Philadelphia, PA. ReDSTM PRO is optimized for the Point-of-Care, designed for use in […]
– APOLLO-B Will Enroll Patients with Both Hereditary and Wild-Type Amyloidosis – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated APOLLO-B, a global Phase 3 placebo-controlled clinical trial of patisiran, an intravenously administered RNAi therapeutic, for the treatment of transthyretin […]
Top-line results projected to be available on or about September 30, 2019 Number of MACE increases from 250 to greater than 275 CALGARY, Alberta, Sept. 16, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today that, following the completion of final patient safety visits (as reported […]
SAN CARLOS, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) — BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial, which included safety […]
WILMINGTON, Del.–(BUSINESS WIRE)– AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure in adults with heart failure with reduced ejection fraction (HFrEF) or […]
CARMAT provided sufficient data to support the initiation of a human clinical study Study to include 5 patients in selected renowned US institutions CARMAT (Paris:ALCAR) (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage […]
